Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer
Study to be Conducted at The University of Texas MD Anderson Cancer Center Mereo BioPharma Group plc; Cancer Focus Fund LONDON, UNITED KINGDOM
LONDON and REDWOOD CITY, Calif. and HOUSTON, Texas, April 30, 2021 (GLOBE NEWSWIRE) Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to provide funding and clinical expertise to advance promising cancer therapies, today announced a partnership to evaluate Mereo’s lead anti-TIGIT therapeutic antibody candidate, etigilimab, in clear cell ovarian cancer, a rare cancer that accounts for approximately 5–10% of all ovarian ca
Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Symbol: AEM Agnico Eagle Mines Limited today reported quarterly net income of $136.1 million or net income of $0.56 per share, for the first quarter of 2021. This result includes gains of $10.0 million on the sale of certain non-core European properties, derivative gains on financial instruments of $6.8 million non-cash foreign currency translation gains of $3.1 million non-cash mark-to-market losses on … (All amounts expressed in U.S. dollars unless otherwise noted) Stock Symbol: AEM (NYSE and TSX)
Agnico Eagle Mines Limited (NYSE: AEM) (TSX: AEM) (“Agnico Eagle” or the “Company”) today reported quarterly net income of $136.1 million or net income of $0.56 per share, for the first quarter of 2021. This result includes gains of $10.0 million ( $0.04 per share) on the sale of certain non-core European properties, derivative gains on financial instruments of $6.8 million ( $0.03 per share), non-cash foreign currency translation gains of $3.1 million ( $0.
CannTrust Announces Change in Auditor
News provided by
Share this article
Share this article
VAUGHAN, ON, April 30, 2021 /PRNewswire/ - CannTrust Holdings Inc. ( CannTrust or the Company ) (unlisted) announced today that CannTrust and KPMG LLP ( KPMG ) have agreed that KPMG will not be completing the audits for the Company s restated financial statements for the years ended December 31, 2018 and 2019 and will not stand for reappointment as the Company s independent auditor for the Company s financial statements for the year ended December 31, 2020.
KPMG has been the Company s independent auditor since December 21, 2018 and, on August 8, 2019, KPMG withdrew its report dated March 27, 2019 on the Company s financial statements for the year ended December 31, 2018 and its interim report to the Audit Committee dated May 13, 2019 on the interim financial statements for the three months ended March 31, 2019. KPMG has not audited any of CannTrust s financial statements for any peri
Published: Apr 30, 2021
LONDON and REDWOOD CITY, Calif. and HOUSTON, Texas, April 30, 2021 (GLOBE NEWSWIRE) Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to provide funding and clinical expertise to advance promising cancer therapies, today announced a partnership to evaluate Mereo’s lead anti-TIGIT therapeutic antibody candidate, etigilimab, in clear cell ovarian cancer, a rare cancer that accounts for approximately 5–10% of all ovarian carcinomas in North America.